Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's Aβ peptide

Taylor, Mark; Moore, Susan A.; Mourtas, Spyridon; Niarakis, Anna; Zona, Cristiano; Ferla, Barbara La; Nicotra, Francesco; Masserini, Massimo; Antimisiaris, Sophia G.; Gregori, Maria

doi:10.1016/j.nano.2011.06.015

Cited by 132 publications

(85 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25 In a series of investigations carried out within the framework of the FP7 EU project known as NAD (Nanoparticles for therapy and diagnosis of Alzheimer's Disease), we designed a series of lipid and polymer-based nanoparticles able to bind with high affinity to aggregate forms of β-amyloid peptide 1,2 and to reduce cytotoxicity 4 or aggregation of the peptide in vitro. 2,27 In order to evaluate cytotoxicity after administration in vivo, we measured nitric oxide production by cultured primary HUVECs and mouse macrophages (RAW264.7 cells) after exposure to these nanoparticles. Certain types of nanoparticles, particularly those composed of silica or metal, have been shown to affect the endothelial system, retarding cell growth, modifying endothelium-dependent vasodilation, and enhancing secretion of proinflammatory cytokines, apoptosis, and/or endothelial cell adhesion (see Supplementary Table).…”

Section: Discussionmentioning

confidence: 99%

Effect of nanoparticles binding ß-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages

Orlando¹,

Sesana²,

Rivolta³

et al. 2013

IJN

Self Cite

View full text Add to dashboard Cite

Background: As part of a project designing nanoparticles for the treatment of Alzheimer's disease, we have synthesized and characterized a small library of nanoparticles binding with high affinity to the β-amyloid peptide and showing features of biocompatibility in vitro, which are important properties for administration in vivo. In this study, we focused on biocompatibility issues, evaluating production of nitric oxide by cultured human umbilical vein endothelial cells and macrophages, used as models of cells which would be exposed to nanoparticles after systemic administration. Methods: The nanoparticles tested were liposomes and solid lipid nanoparticles carrying phosphatidic acid or cardiolipin, and PEGylated poly(alkyl cyanoacrylate) nanoparticles (PEG-PACA). We measured nitric oxide production using the Griess method as well as phosphorylation of endothelial nitric oxide synthase and intracellular free calcium, which are biochemically related to nitric oxide production. MTT viability tests and caspase-3 detection were also undertaken. Results: Exposure to liposomes did not affect the viability of endothelial cells at any concentration tested. Increased production of nitric oxide was detected only with liposomes carrying phosphatidic acid or cardiolipin at the highest concentration (120 µg/mL), together with increased synthase phosphorylation and intracellular calcium levels. Macrophages exposed to liposomes showed a slightly dose-dependent decrease in viability, with no increase in production of nitric oxide. Exposure to solid lipid nanoparticles carrying phosphatidic acid decreased viability in both cell lines, starting at the lowest dose (10 µg/mL), with increased production of nitric oxide detected only at the highest dose (1500 µg/mL). Exposure to PEG-PACA affected cell viability and production of nitric oxide in both cell lines, but only at the highest concentration (640 µg/mL). Conclusion: Liposomal and PEG-PACA nanoparticles have a limited effect on vascular homeostasis and inflammatory response, rendering them potentially suitable for treatment of Alzheimer's disease. Moreover, they highlight the importance of testing such nanoparticles for production of nitric oxide in vitro in order to identify a therapeutic dose range suitable for use in vivo.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of nanoparticles binding ß-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages

Orlando¹,

Sesana²,

Rivolta³

et al. 2013

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some among them are targeted against NDDs. A curcuminpyrazole-polyethylenglycol (PEG) lipid conjugate [184] protrudes from liposomes (≈200 nm mean diameter) and inhibits Ab 42 aggregation in a dose-dependent manner, while lipid-conjugated liposomes are inactive [184]. Water-soluble, poly-(lactic-co-glycolic acid) (PLGA) nanoparticles (150-200 nm mean diameter) decorated with a motor neuron-targeting Tet-1 peptide encapsulate curcumin, promote its bioavailability and biological activity [185].…”

Section: Interfering With (Neuro)toxic Tau Species In the Aggregationmentioning

confidence: 99%

Targeting Assembly and Disassembly of Protein Aggregates

Seneci

2015

Chemical Modulators of Protein Misfolding and Neurodegenerative Disease

View full text Add to dashboard Cite

“…Recently, Hiesh et al curcumin, phosphatidic acid, cardiolipin, or GM1 ganglioside, the click-curcumin type being by far the most effective [283]. Unfortunately, no in vivo experiments have been performed.…”

Section: A) Nanoparticle-mediated Protein Aggregation Manipulationmentioning

confidence: 99%

Diagnostic and Therapeutic Uses of Nanomaterials in the Brain

Garbayo¹,

Mendoza²,

Blanco-Prieto

2014

CMC

View full text Add to dashboard Cite

Nanomedicine has recently emerged as an exciting tool able to improve the early diagnosis and treatment of a variety of intractable or age-related brain disorders. The most relevant properties of nanomaterials are that they can be engineered in such a way that they can cross the blood brain barrier, with the final aim of targeting specific cells and molecules and to act as vehicles for drugs. Potentially beneficial properties of nanotherapeutics derived from its unique characteristics include improved efficacy, safety, sensitivity and personalization compared to conventional medicines.In this review, recent advances in available nanostructures and nanomaterials for brain applications will be described. Then, the latest nanotechnological applications for the treatment and diagnosis of neurological disorders, mainly brain tumors and neurodegenerative diseases, will be reviewed. Recent investigations of the neurotoxicity of the nanomaterial both in vitro and in vivo will be summarized. Finally, the ongoing challenges that have to be meet if new nanomedical products are to be put on the market will be discussed and some future directions will be outlined.

show abstract

Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's Aβ peptide

Cited by 132 publications

References 41 publications

Effect of nanoparticles binding ß-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages

Effect of nanoparticles binding ß-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages

Targeting Assembly and Disassembly of Protein Aggregates

Diagnostic and Therapeutic Uses of Nanomaterials in the Brain

Contact Info

Product

Resources

About

Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's Aβ peptide

Cited by 132 publications

References 41 publications

Effect of nanoparticles binding &szlig;-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages

Effect of nanoparticles binding &szlig;-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages

Targeting Assembly and Disassembly of Protein Aggregates

Diagnostic and Therapeutic Uses of Nanomaterials in the Brain

Contact Info

Product

Resources

About

Effect of nanoparticles binding ß-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages

Effect of nanoparticles binding ß-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages